Company
Insilico Medicine
- Latest development
- Aug 21, 2026
- Published intelligence
- 1
- Active developments
- 0
Follow Insilico Medicine to track meaningful changes across developments involving Insilico Medicine.
Latest intelligence
- MIT Technology Review
When AI designs a drug, who gets the credit?
Biotechnology companies such as Insilico Medicine are leveraging generative AI platforms to design novel therapeutic molecules, including candidate treatments for pulmonary fibrosis. As machine learning systems take on primary roles in proposing chemical structures, ambiguity arises over legal inventorship, scientific attribution, and intellectual property eligibility. Global patent authorities and pharmaceutical firms must address how algorithmic drug designs align with traditional legal requirements that mandate human inventorship.